Tremfya Shows Sustained Remission Through Three Years in Crohn’s Disease
Tremfya (guselkumab) demonstrated sustained clinical and endoscopic remission through three years in moderately to severely active Crohn’s disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.